Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
This was 1 month ago
LocationOnline
ProgrammesThis event is the first in a three-event series promoting European cooperation in addressing research security challenges hosted by EARMA.
Each session will provide practical support to research managers including discussion of case studies, signposting to publicly available tools and resources, and commercially available products.
Event details:
Here you can find information about the next events in this series:
2) Resources for managing research security risks (November 15th 2024)
3) Products to support research security management (December 12th 2024)
For more information on these events and the full agenda, please access the dedicated event page.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Enhancing EU R&I Horizon Europe
Health Agro-Food, Environment EIC EIT
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.